Skip to main content

Advertisement

SpringerLink
Log in

Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate diagnostic and prognostic significance of plasma osteopontin (OPN) in patients with renal cell carcinoma (RCC).

Methods

The retrospective study included 80 patients with RCC (pN0M0, n = 32; pN1M0, n = 11; M1, and n = 37), and 52 healthy controls (27 females and 25 males). OPN, the bone marker bone-specific alkaline phosphatase (bALP) and carboxyterminal telopetide of type-I collagen (ICTP), and the enzymes alanine aminotransferase (ALAT), and gamma-glutamyltransferase (GGT) were evaluated together with Memorial Sloan-Kettering Cancer Center (MSKCC) laboratory parameters. Data were analyzed by receiver–operating characteristics (ROC), survival analysis, and Cox proportional hazards regression model.

Results

OPN and ICTP levels in RCC patients with distant metastases were significantly elevated (medians 115 and 4.7 μg/l, P < 0.001) compared to those without metastases (31.1 and 2.5 μg/l) and controls (28.9 and 2.1 μg/l) but did not differ between patients with bone or non-bone metastases. Both bALP and ALAT were not different between all study groups, while GGT was only increased in patients with non-bone metastases. In ROC analysis, OPN showed the best discrimination between patients with and without metastases (area under the curve: 0.888). High OPN values were associated with poor survival (Kaplan–Meier analysis, log-rank test, P = 0.002). Multivariate Cox regression with forward and backward stepwise elimination confirmed plasma OPN as independent predictive survival factor in RCC patients.

Conclusions

Our results show that high plasma OPN levels are associated with distant metastases and poor survival in RCC patients. The use of OPN as potential marker to monitor new treatment strategies in patients with advanced RCC should be evaluated in prospective studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

OPN:

Osteopontin

RCC:

Renal cell carcinoma

bALP:

Bone-specific alkaline phosphatase

ICTP:

Carboxyterminal telopetide of type I collagen

ALAT:

Alanine aminotransferase

GGT:

Gamma-glutamyltransferase

LDH:

Lactate dehydrogenase

Ca:

Calcium

tALP:

Total alkaline phosphatase

Hb:

Hemoglobin

ROC:

Receiver–operation characteristics

95% CI:

95% Confidence interval

References

  • Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513–521

    PubMed  CAS  Google Scholar 

  • Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI (2005) Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 96:803–805

    Article  PubMed  CAS  Google Scholar 

  • Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12:3337–3343

    Article  PubMed  CAS  Google Scholar 

  • Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas NJ, Rio J, Montalban X (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158:231–239

    Article  PubMed  CAS  Google Scholar 

  • Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190

    Article  PubMed  CAS  Google Scholar 

  • Das R, Mahabeleshwar GH, Kundu GC (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278:28593–28606

    Article  PubMed  CAS  Google Scholar 

  • Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060–4066

    PubMed  CAS  Google Scholar 

  • Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1:621–632

    Article  PubMed  CAS  Google Scholar 

  • Henry NL, Hayes DF (2006) Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11:541–552

    Article  PubMed  CAS  Google Scholar 

  • Hirama M, Takahashi F, Takahashi K, Akutagawa S, Shimizu K, Soma S, Shimanuki Y, Nishio K, Fukuchi Y (2003) Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 198:107–117

    Article  PubMed  CAS  Google Scholar 

  • Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 95:506–512

    Article  PubMed  CAS  Google Scholar 

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66

    Article  PubMed  Google Scholar 

  • Kashyap MK, Kumar A, Emelianenko N, Kashyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK, Bhargave AK, Upadhyaya SK (2005) Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 10:258–294

    Article  PubMed  CAS  Google Scholar 

  • Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287:1671–1679

    Article  PubMed  CAS  Google Scholar 

  • Koga S, Tsuda S, Nishikido M, Ogawa Y, Hayashi K, Hayashi T, Kanetake H (2001) The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 166:2126–2128

    Article  PubMed  CAS  Google Scholar 

  • Kriteman L, Sanders WH (1998) Normal alkaline phosphatase levels in patients with bone metastases due to renal cell carcinoma. Urology 51:397–399

    Article  PubMed  CAS  Google Scholar 

  • Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59–67

    PubMed  CAS  Google Scholar 

  • Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296

    Article  PubMed  CAS  Google Scholar 

  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    PubMed  CAS  Google Scholar 

  • Orrell DH (1971) Albumin as an aid to the interpretation of serum calcium. Clin Chim Acta 35:483–489

    Article  PubMed  CAS  Google Scholar 

  • Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87

    Article  PubMed  CAS  Google Scholar 

  • Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (2005) SEER cancer statistics review, 1975–2002. National Cancer Institute, Bethesda, MD

    Google Scholar 

  • Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90:1877–1881

    Article  PubMed  CAS  Google Scholar 

  • Rittling SR, Denhardt DT (1999) Osteopontin function in pathology: lessons from osteopontin-deficient mice. Exp Nephrol 7:103–113

    Article  PubMed  CAS  Google Scholar 

  • Rousseau T, Peyret C, Zerbib M, Thiounn N, Flam T, Debre B (1994) Circumstances of the detection of kidney cancer. Current part of accidental discoveries. J Urol (Paris) 100:189–195

    CAS  Google Scholar 

  • Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM (1998) NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 141:1083–1093

    Article  PubMed  CAS  Google Scholar 

  • Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E, Imamura M (2005) Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 68:285–292

    Article  PubMed  CAS  Google Scholar 

  • Singhal H, Bautista DS, Tonkin KS, O’Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605–611

    PubMed  CAS  Google Scholar 

  • Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26:179–184

    PubMed  CAS  Google Scholar 

  • Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF (2000) Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78:465–475

    Article  PubMed  CAS  Google Scholar 

  • Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP (2005) Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 31:555–558

    Article  PubMed  CAS  Google Scholar 

  • Yoneda T (2006) Pathophysiology of osteolytic bone metastasis associated with solid cancers. Clin Calcium 16:16–24

    Google Scholar 

  • Zekri J, Ahmed N, Coleman RE, Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19:379–382

    PubMed  CAS  Google Scholar 

  • Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, Sun HC, Wang L, Zhang BH, Liu YK, Tang ZY, Qin LX (2006) The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 132:709–717

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Azizbek Ramankulov is supported by a grant from the German Academic Exchange Service. We thank Silke Klotzek and Janett Reiche for excellent technical assistance.

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital Charité, Charité—University Medicine Berlin, Campus Charité Mitte, Schumannstrasse 20/21, 10098, Berlin, Germany

    Azizbek Ramankulov, Michael Lein, Hellmuth-A. Meyer, Stefan A. Loening & Klaus Jung

  2. Institute of Pathology, Charité—University Medicine Berlin, Campus Charité Mitte, 10098, Berlin, Germany

    Glen Kristiansen

  3. Republic Center of Urology, Bishkek, Kyrgyz Republic

    Azizbek Ramankulov

Authors
  1. Azizbek Ramankulov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Lein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glen Kristiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hellmuth-A. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefan A. Loening
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Klaus Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Jung.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramankulov, A., Lein, M., Kristiansen, G. et al. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 133, 643–652 (2007). https://doi.org/10.1007/s00432-007-0215-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-007-0215-z

Keywords

Search

Navigation